Saro H Armenian1, Smita Bhatia. 1. Department of Population Sciences, City of Hope National Medical Center, Duarte, CA, USA.
Abstract
BACKGROUND: High-intensity, risk-based therapeutic strategies for childhood cancer have resulted in long-term survival rates that now approach 80%. However, the growing population of survivors is at a substantial risk for treatment-related complications that can significantly impact quantity and quality of survival. It is increasingly recognized that many of these complications result from complex interactions between therapeutic exposures and genetic susceptibility. OBJECTIVE: This review is designed to increase general clinician awareness of the ongoing efforts by investigators to understand the interactions between therapeutic exposures and genetic susceptibility to therapy-related complications. RESULTS: Most studies have relied on a biologically plausible candidate gene approach to evaluate genetic susceptibility. This has resulted in the identification of unique genetic polymorphisms that could alter metabolic pathways of therapeutic agents associated with specific adverse events. We highlight some of these findings and discuss their implications for future prevention strategies, as well as their role in elucidating the pathophysiology of these complex diseases. CONCLUSION: Research exploring the role of genetic susceptibility in the development of therapy-related adverse outcomes is still in its infancy. There is a need for continued efforts to study these outcomes in the context of complex gene-gene and gene-environment interactions unique to cancer survivors. A better understanding of the pathogenesis of these outcomes will help develop effective targeted prevention strategies.
BACKGROUND: High-intensity, risk-based therapeutic strategies for childhood cancer have resulted in long-term survival rates that now approach 80%. However, the growing population of survivors is at a substantial risk for treatment-related complications that can significantly impact quantity and quality of survival. It is increasingly recognized that many of these complications result from complex interactions between therapeutic exposures and genetic susceptibility. OBJECTIVE: This review is designed to increase general clinician awareness of the ongoing efforts by investigators to understand the interactions between therapeutic exposures and genetic susceptibility to therapy-related complications. RESULTS: Most studies have relied on a biologically plausible candidate gene approach to evaluate genetic susceptibility. This has resulted in the identification of unique genetic polymorphisms that could alter metabolic pathways of therapeutic agents associated with specific adverse events. We highlight some of these findings and discuss their implications for future prevention strategies, as well as their role in elucidating the pathophysiology of these complex diseases. CONCLUSION: Research exploring the role of genetic susceptibility in the development of therapy-related adverse outcomes is still in its infancy. There is a need for continued efforts to study these outcomes in the context of complex gene-gene and gene-environment interactions unique to cancer survivors. A better understanding of the pathogenesis of these outcomes will help develop effective targeted prevention strategies.
Authors: C A Sklar; A C Mertens; A Walter; D Mitchell; M E Nesbit; M O'Leary; R Hutchinson; A T Meadows; L L Robison Journal: Med Pediatr Oncol Date: 2000-08
Authors: G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper Journal: N Engl J Med Date: 2000-04-13 Impact factor: 91.245
Authors: Smita Bhatia; Saro H Armenian; Gregory T Armstrong; Eline van Dulmen-den Broeder; Michael M Hawkins; Leontien C M Kremer; Claudia E Kuehni; Jørgen H Olsen; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Saro H Armenian; Gregory T Armstrong; Gregory Aune; Eric J Chow; Matthew J Ehrhardt; Bonnie Ky; Javid Moslehi; Daniel A Mulrooney; Paul C Nathan; Thomas D Ryan; Helena J van der Pal; Elvira C van Dalen; Leontien C M Kremer Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Saro H Armenian; Dongyun Yang; Jennifer Berano Teh; Liezl C Atencio; Alicia Gonzales; F Lennie Wong; Wendy M Leisenring; Stephen J Forman; Ryotaro Nakamura; Eric J Chow Journal: Blood Adv Date: 2018-07-24
Authors: Eric J Chow; Kirsten K Ness; Gregory T Armstrong; Nickhill Bhakta; Jennifer M Yeh; Smita Bhatia; Wendy Landier; Louis S Constine; Melissa M Hudson; Paul C Nathan Journal: Semin Oncol Date: 2020-03-04 Impact factor: 4.929
Authors: Nan Song; Chia-Wei Hsu; Haitao Pan; Yinan Zheng; Lifang Hou; Jin-Ah Sim; Zhenghong Li; Heather Mulder; John Easton; Emily Walker; Geoffrey Neale; Carmen L Wilson; Kirsten K Ness; Kevin R Krull; Deo Kumar Srivastava; Yutaka Yasui; Jinghui Zhang; Melissa M Hudson; Leslie L Robison; I-Chan Huang; Zhaoming Wang Journal: Genome Med Date: 2021-04-06 Impact factor: 11.117